Previous 10 | Next 10 |
SAN DIEGO, April 12, 2021 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announc...
Truist Securities has upgraded AnaptysBio ([[ANAB]] +6.1%) to buy from hold citing the recent selloff following the company’s failure of the mid-stage trial for Imsidolimab in moderate-to-severe palmoplantar pustulosis.Upped by more than a quarter from the previous, the new price targe...
Shares of clinical-stage biotech AnaptysBio (NASDAQ: ANAB) were rising sharply on Tuesday following bullish commentary from a Wall Street analyst. The company's stock was up by 5.6% as of 12:58 p.m. EDT, after rising by as much as 12% earlier in the day. Truist analyst Joon Lee ...
Listen on the go! A daily podcast of Wall Street Breakfast's Alpha Talks will be available this morning on Seeking Alpha, iTunes, Stitcher and Spotify. A round of late-afternoon buying boosted the Dow Jones average to another record high on Friday as rising optimism around the global economic...
Tech investors who are glum about the recent performances of their holdings have nothing on AnaptysBio (NASDAQ: ANAB) . The clinical-stage biotech's shares fell off a cliff on Monday, dropping nearly 34% on very discouraging news about a clinical study. AnaptysBio announced that...
AnaptysBio ([[ANAB]] -35.3%) has lost more than a third today following its pre-market announcement of the failure of imsidolimab to meet the primary endpoint in a mid-stage study for moderate-to-severe palmoplantar pustulosis.Citing questions for long-term value creation path follo...
Gainers: Second Sight Medical Products (EYES) +94%.OpGen (OPGN) +71%.Anchiano Therapeutics (ANCN) +66%.GameStop (GME) +44%.Jaguar Health (JAGX) +35%.Moxian (MOXC) +30%.Koss (KOSS) +30%.Idera Pharmaceuticals (IDRA) +28%.BSQUARE (BSQR) +25%.Greenwich LifeSciences (GLSI) +23%.Losers:...
Gainers: Second Sight Medical Products (EYES) +92%, OpGen (OPGN) +79%, Anchiano Therapeutics (ANCN) +64%, Jaguar Health (JAGX) +29%, Idera Pharmaceuticals (IDRA) +22%.Losers: Soleno Therapeutics (SLNO) -44%, AnaptysBio (ANAB) -34%, T...
AnaptysBio ([[ANAB]] -34.6%) is trading sharply lower today after the company announced that the Phase 2 trial for Imsidolimab (previously ANB019) failed to meet the primary endpoint in moderate-to-severe palmoplantar pustulosis with a statistically meaningful impact.The company rul...
Imsidolimab treatment did not demonstrate statistically significant improvement over placebo in PPPASI change from baseline at week 16 primary endpoint Imsidolimab was generally well tolerated and no serious or severe adverse events were reported in the drug arm of the trial Anapt...
News, Short Squeeze, Breakout and More Instantly...
A look at the top 10 most actives in the United States 60 Degrees Pharmaceuticals Inc. (SXTP) rose 98.3% to $0.4878 on volume of 116,444,604 shares NVIDIA Corporation (NVDA) fell 0.2% to $120.8 on volume of 26,900,560 shares Serve Robotics Inc. (SERV) rose 61.2% to $4.2399 on volume of 25...
2024-05-10 18:15:02 ET Wells Fargo analyst issues BUY recommendation for ANAB on May 10, 2024 05:01PM ET. The previous analyst recommendation was Buy. ANAB was trading at $23.41 at issue of the analyst recommendation. The overall analyst consensus : HOLD. Current ana...
Enrollment ongoing for global Phase 2b trial to treat atopic dermatitis (AD) with ANB032, our BTLA agonist; reiterating top-line data anticipated by year-end 2024 Enrollment ongoing for global Phase 2b trial to treat rheumatoid arthritis (RA) and global Phase 2 trial to treat ulcerative colit...